News
The stock has been in free fall since safety issues derailed a gene therapy analysts had expected to achieve blockbuster ...
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...
Stocktwits on MSN41m
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback